Zura Bio Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.2%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.72next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| TibuSHIELD (HS) Phase 2 Topline Data Readout | 31 Dec 2026 |
| TibuSURE (SSc) Phase 2 Topline Data Readout | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
Tibulizumab (ZB-106) Phase 2 TibuSHIELD Trial Enrollment Quarterly225.0Target: 225 participants (fully enrolled/on track)
Cash and Cash Equivalents Quarterly225.6MTarget: Sufficient to fund operations through at least the end of 2028
Quarterly Research and Development (R&D) Expenses Quarterly14.7MTarget: Reflects continued advancement of Phase 2 clinical programs
Watch Items
- TibuSHIELD Phase 2 Topline Data Readout in Hidradenitis Suppurativa (HS)Trigger: Q4 2026Action: Evaluate clinical efficacy, safety, and competitive differentiation of dual IL-17A/BAFF inhibition compared to single-pathway therapies.
- TibuSURE Phase 2 Topline Data Readout in Systemic Sclerosis (SSc)Trigger: H1 2027Action: Assess clinical efficacy and safety endpoints in early diffuse cutaneous systemic sclerosis (dcSSc).
- Cash Runway and Burn RateTrigger: Cash balance falling below $100 million or runway dropping below 18 monthsAction: Re-evaluate clinical trial timelines, prioritize pipeline assets, or explore strategic partnerships and non-dilutive financing options.
Research as of 20 Jun 2026